不同药理类型抗癌药物所致间质性肺病患者的预后。
Prognosis of Patients With Interstitial Lung Disease Induced by Different Pharmacological Types of Anticancer Drugs.
机构信息
Department of Clinical Pharmacy, Fujita Health University School of Medicine, Toyoake, Japan.
Department of Clinical Pharmacy, Fujita Health University School of Medicine, Toyoake, Japan;
出版信息
Anticancer Res. 2021 May;41(5):2563-2568. doi: 10.21873/anticanres.15034.
BACKGROUND/AIM: The aim of this study was to evaluate the effect of drug-induced interstitial lung disease (DILD) on treatment outcomes by comparing the mortality of patients with DILD induced by different pharmacological types of anticancer drugs.
PATIENTS AND METHODS
Japanese patients with lung cancer who had received chemotherapy at Fujita Health University Hospital were enrolled. The primary outcome was the short-term mortality rate from the administration of chemotherapy that might have caused DILD.
RESULTS
Eleven, 16, and 20 patients with DILD were assigned to the kinase inhibitor (KI), immune-checkpoint inhibitor (ICI), and cytotoxic anticancer drug groups, respectively. The 90-day mortality rate after the DILD event in the group treated with cytotoxic anticancer drugs was significantly higher than in the KI and ICI groups.
CONCLUSION
Patients with DILD induced by cytotoxic anticancer drugs have poorer prognoses than those with DILD induced by KIs or ICIs.
背景/目的：本研究旨在通过比较不同药理类型抗癌药物引起的药物性间质性肺病（DILD）对治疗结果的影响，评估 DILD 对治疗结果的影响。
患者和方法
在藤田保健卫生大学医院接受化疗的肺癌日本患者被纳入本研究。主要结局是可能因 DILD 而导致化疗的短期死亡率。
结果
DILD 患者分别被分配到激酶抑制剂（KI）、免疫检查点抑制剂（ICI）和细胞毒性抗癌药物组，每组分别有 11、16 和 20 例。细胞毒性抗癌药物组在 DILD 事件后 90 天的死亡率明显高于 KI 和 ICI 组。
结论
与由 KI 或 ICI 引起的 DILD 相比，由细胞毒性抗癌药物引起的 DILD 患者的预后更差。
Zotero 插件